SWOG clinical trial number
CTSU/EA5163/S1709

INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-Driven Analysis

Closed
Abbreviated Title
INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung…
Status Notes
Site FAQ regarding background, eligibility, treatment, funding, and resources are available on the CTSU website under Protocol Related Documents http://www.ctsu.org.
Activated
02/28/2019
Closed
03/01/2024
Participants
CTSU

Research committees

Lung Cancer

Eligibility Criteria Expand/Collapse

SWOG Cancer Research Network has endorsed this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.

Please contact the CTSU directly by either phone (1-888-823-5923) or on the CTSU web site (http://www.ctsu.org/) for more information and registration procedures.

Other Clinical Trials

SWOG Clinical Trial Number
A082302

EVALUATING ADJUVANT ATEZOLIZUMAB OR ATEZOLIZUMAB AND HYALURONIDASE-TQJS TO PREVENT RECURRENCE IN STAGE I NON-SMALL CELL LUNG CANCER (NSCLC): A RANDOMIZED PHASE III TRIAL (AASI-NSCLC)
Research Committee(s)
Lung Cancer
Activated
03/02/2027
Open
SWOG Clinical Trial Number
S2409

PRISM: PRecIsion in SCLC via a Multicohort Study: Randomized Phase II studies evaluating maintenance Durvalumab with or without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Research Committee(s)
Lung Cancer
Activated
09/08/2025
Accrual
2%
Open
Phase
SWOG Clinical Trial Number
CTSU/EA5231

A Randomized Phase III Trial of Checkpoint Blockade in Lung Cance3r Patients in the Adjuvant Setting Based on Pathologic Response Following Neoadjuvant Therapy (CLEAR)
Research Committee(s)
Lung Cancer
Activated
06/13/2025
Open
Phase